Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).
Germany
Hematologic Neoplasms
/ therapy
Hematology
Hematopoietic Stem Cell Transplantation
Hepacivirus
/ metabolism
Hepatitis B
/ blood
Hepatitis B Antibodies
/ blood
Hepatitis B virus
/ metabolism
Hepatitis C
/ blood
Humans
Medical Oncology
Pneumocystis carinii
/ metabolism
Pneumonia, Pneumocystis
/ blood
Practice Guidelines as Topic
RNA, Viral
/ blood
Societies, Medical
Transplantation, Autologous
Trimethoprim, Sulfamethoxazole Drug Combination
/ therapeutic use
Autologous stem cell transplantation
Infection
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
06
07
2020
accepted:
03
10
2020
pubmed:
21
10
2020
medline:
27
1
2021
entrez:
20
10
2020
Statut:
ppublish
Résumé
To ensure the safety of high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT), evidence-based recommendations on infectious complications after HDC/ASCT are given. This guideline not only focuses on patients with haematological malignancies but also addresses the specifics of HDC/ASCT patients with solid tumours or autoimmune disorders. In addition to HBV and HCV, HEV screening is nowadays mandatory prior to ASCT. For patients with HBs antigen and/or anti-HBc antibody positivity, HBV nucleic acid testing is strongly recommended for 6 months after HDC/ASCT or for the duration of a respective maintenance therapy. Prevention of VZV reactivation by vaccination is strongly recommended. Cotrimoxazole for the prevention of Pneumocystis jirovecii is supported. Invasive fungal diseases are less frequent after HDC/ASCT, therefore, primary systemic antifungal prophylaxis is not recommended. Data do not support a benefit of protective room ventilation e.g. HEPA filtration. Thus, AGIHO only supports this technique with marginal strength. Fluoroquinolone prophylaxis is recommended to prevent bacterial infections, although a survival advantage has not been demonstrated.
Identifiants
pubmed: 33079221
doi: 10.1007/s00277-020-04297-8
pii: 10.1007/s00277-020-04297-8
pmc: PMC7572248
doi:
Substances chimiques
Hepatitis B Antibodies
0
RNA, Viral
0
Trimethoprim, Sulfamethoxazole Drug Combination
8064-90-2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
321-336Références
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P, Study IFM (2017) Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 376(14):1311–1320. https://doi.org/10.1056/NEJMoa1611750
doi: 10.1056/NEJMoa1611750
pubmed: 28379796
pmcid: 6201242
Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hanel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Duhrsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M, European Mantle Cell Lymphoma N (2016) Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 388(10044):565–575. https://doi.org/10.1016/S0140-6736(16)00739-X
doi: 10.1016/S0140-6736(16)00739-X
pubmed: 27313086
Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Keller U, Dreger P, Dreyling M, Hiddemann W, Unterhalt M, Hoster E, Weigert O (2018) Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group. Biol Blood Marrow Transplant 24(6):1172–1179. https://doi.org/10.1016/j.bbmt.2018.03.022
doi: 10.1016/j.bbmt.2018.03.022
pubmed: 29605716
Christopeit M, Labopin M, Gorin NC, Saraceni F, Passweg J, Forcade E, Maertens J, Van Lint MT, Bosi A, Niederwieser D, Ehninger G, Polge E, Mohty M, Nagler A (2018) Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: a retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. Am J Hematol 93(12):1532–1542. https://doi.org/10.1002/ajh.25285
doi: 10.1002/ajh.25285
pubmed: 30218444
Pagliaro LC (2017) Role of high-dose chemotherapy with autologous stem-cell rescue in men with previously treated germ cell tumors. J Clin Oncol 35(10):1036–1040. https://doi.org/10.1200/JCO.2016.70.6523
doi: 10.1200/JCO.2016.70.6523
pubmed: 27992270
Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trneny M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R, Multiple Sclerosis-Autologous Hematopoietic Stem Cell Transplantation Long-term Outcomes Study G (2017) Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurology 74(4):459–469. https://doi.org/10.1001/jamaneurol.2016.5867
doi: 10.1001/jamaneurol.2016.5867
pubmed: 28241268
pmcid: 5744858
Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE, Investigators SS (2018) Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 378(1):35–47. https://doi.org/10.1056/nejmoa1703327
doi: 10.1056/nejmoa1703327
pubmed: 29298160
pmcid: 5846574
Brierley CK, Castilla-Llorente C, Labopin M, Badoglio M, Rovira M, Ricart E, Dierickx D, Vermeire S, Hasselblatt P, Finke J, Onida F, Cassinotti A, Satsangi J, Kazmi M, Lopez-Sanroman A, Schmidt C, Farge D, Travis SPL, Hawkey CJ, Snowden JA, European Society for B, Marrow Transplantation Autoimmune Diseases Working P (2018) Autologous haematopoietic stem cell transplantation for Crohn's disease: a retrospective survey of long-term outcomes from the European Society for Blood and Marrow Transplantation. J Crohn's Colitis 12(9):1097–1103. https://doi.org/10.1093/ecco-jcc/jjy069
doi: 10.1093/ecco-jcc/jjy069
Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, Dolstra H, Lankester AC, Mohty M, Montoto S, Peffault de Latour R, Snowden JA, Styczynski J, Yakoub-Agha I, Kroger N, European Society for B, Marrow T (2020) The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transplant 55(8):1604–1613. https://doi.org/10.1038/s41409-020-0826-4
doi: 10.1038/s41409-020-0826-4
pubmed: 32066864
pmcid: 7391287
Signorelli J, Zimmer A, Liewer S, Shostrom VK, Freifeld A (2020) Incidence of febrile neutropenia in autologous hematopoietic stem cell transplant (HSCT) recipients on levofloxacin prophylaxis. Transpl Infect Dis 22(2):e13225. https://doi.org/10.1111/tid.13225
doi: 10.1111/tid.13225
pubmed: 31785022
Girmenia C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A, Cattaneo C, Raiola AM, Guidi S, Iori AP, Candoni A, Irrera G, Milone G, Marcacci G, Scime R, Musso M, Cudillo L, Sica S, Castagna L, Corradini P, Marchesi F, Pastore D, Alessandrino EP, Annaloro C, Ciceri F, Santarone S, Nassi L, Farina C, Viscoli C, Rossolini GM, Bonifazi F, Rambaldi A, Gruppo Italiano Trapianto di Midollo O, Associazione Microbiologi Clinici I (2017) Incidence, risk factors and outcome of pre-engraftment Gram-negative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: an Italian prospective multicenter survey. Clin Infect Dis 65(11):1884–1896. https://doi.org/10.1093/cid/cix690
doi: 10.1093/cid/cix690
pubmed: 29020286
Averbuch D, Tridello G, Hoek J, Mikulska M, Akan H, Yanez San Segundo L, Pabst T, Ozcelik T, Klyasova G, Donnini I, Wu D, Gulbas Z, Zuckerman T, Botelho de Sousa A, Beguin Y, Xhaard A, Bachy E, Ljungman P, de la Camara R, Rascon J, Ruiz Camps I, Vitek A, Patriarca F, Cudillo L, Vrhovac R, Shaw PJ, Wolfs T, O'Brien T, Avni B, Silling G, Al Sabty F, Graphakos S, Sankelo M, Sengeloev H, Pillai S, Matthes S, Melanthiou F, Iacobelli S, Styczynski J, Engelhard D, Cesaro S (2017) Antimicrobial resistance in Gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clin Infect Dis 65(11):1819–1828. https://doi.org/10.1093/cid/cix646
doi: 10.1093/cid/cix646
pubmed: 29020364
Marchesi F, Pimpinelli F, Di Domenico EG, Renzi D, Gallo MT, Regazzo G, Rizzo MG, Gumenyuk S, Toma L, Marino M, Cordone I, Cantonetti M, Liberati AM, Montanaro M, Ceribelli A, Prignano G, Palombi F, Romano A, Papa E, Pisani F, Spadea A, Arcese W, Ensoli F, Mengarelli A (2019) Association between CMV and invasive fungal infections after autologous stem cell transplant in lymphoproliferative malignancies: opportunistic partnership or cause-effect relationship? Int J Mol Sci 20(6). https://doi.org/10.3390/ijms20061373
Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50(8):1091–1100. https://doi.org/10.1086/651263
doi: 10.1086/651263
pubmed: 20218877
Maschmeyer G, Hertenstein B, Glass B, Schiel X (1999) Interventional antimicrobial therapy for febrile complications after high-dose chemotherapy and autologous stem cell transplantation. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology. Dtsch Med Wochenschr 124(Suppl 1):S9–S13
Bertz H, Auner HW, Weissinger F, Salwender HJ, Einsele H, Egerer G, Sandherr M, Schuttrumpf S, Sudhoff T, Maschmeyer G, Infectious Diseases Working Party of the German Society of H, Oncology (2003) Antimicrobial therapy of febrile complications after high-dose chemo−/radiotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82 Suppl 2:S167–S174. doi: https://doi.org/10.1007/s00277-003-0771-5
Weissinger F, Auner HW, Bertz H, Buchheidt D, Cornely OA, Egerer G, Heinz W, Karthaus M, Kiehl M, Kruger W, Penack O, Reuter S, Ruhnke M, Sandherr M, Salwender HJ, Ullmann AJ, Waldschmidt DT, Wolf HH (2012) Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 91(8):1161–1174. https://doi.org/10.1007/s00277-012-1456-8
doi: 10.1007/s00277-012-1456-8
pubmed: 22638755
Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H, Karthaus M, Link H, Mahlberg R, Neumann S, Ostermann H, Penack O, Ruhnke M, Sandherr M, Schiel X, Vehreschild JJ, Weissinger F, Maschmeyer G (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96(11):1775–1792. https://doi.org/10.1007/s00277-017-3098-3
doi: 10.1007/s00277-017-3098-3
pubmed: 28856437
pmcid: 5645428
Penack O, Becker C, Buchheidt D, Christopeit M, Kiehl M, von Lilienfeld-Toal M, Hentrich M, Reinwald M, Salwender H, Schalk E, Schmidt-Hieber M, Weber T, Ostermann H (2014) Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Ann Hematol 93(7):1083–1095. https://doi.org/10.1007/s00277-014-2086-0
doi: 10.1007/s00277-014-2086-0
pubmed: 24777705
pmcid: 4050292
Ruhnke M, Behre G, Buchheidt D, Christopeit M, Hamprecht A, Heinz W, Heussel CP, Horger M, Kurzai O, Karthaus M, Loffler J, Maschmeyer G, Penack O, Rieger C, Rickerts V, Ritter J, Schmidt-Hieber M, Schuelper N, Schwartz S, Ullmann A, Vehreschild JJ, von Lilienfeld-Toal M, Weber T, Wolf HH (2018) Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO). Mycoses 61(11):796–813. https://doi.org/10.1111/myc.12838
doi: 10.1111/myc.12838
pubmed: 30098069
Ruhnke M, Cornely OA, Schmidt-Hieber M, Alakel N, Boell B, Buchheidt D, Christopeit M, Hasenkamp J, Heinz WJ, Hentrich M, Karthaus M, Koldehoff M, Maschmeyer G, Panse J, Penack O, Schleicher J, Teschner D, Ullmann AJ, Vehreschild M, von Lilienfeld-Toal M, Weissinger F, Schwartz S (2020) Treatment of invasive fungal diseases in cancer patients - Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Mycoses 63(7):653–682. https://doi.org/10.1111/myc.13082
doi: 10.1111/myc.13082
pubmed: 32236989
Maschmeyer G, Carratala J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, Lorenz J, Neumann S, Rieger C, Ruhnke M, Salwender H, Schmidt-Hieber M, Azoulay E (2015) Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 26(1):21–33. https://doi.org/10.1093/annonc/mdu192
doi: 10.1093/annonc/mdu192
pubmed: 24833776
pmcid: 4269340
Schmidt-Hieber M, Bierwirth J, Buchheidt D, Cornely OA, Hentrich M, Maschmeyer G, Schalk E, Vehreschild JJ, Vehreschild M, Group AW (2018) Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 97(1):31–49. https://doi.org/10.1007/s00277-017-3183-7
doi: 10.1007/s00277-017-3183-7
pubmed: 29177551
Hentrich M, Schalk E, Schmidt-Hieber M, Chaberny I, Mousset S, Buchheidt D, Ruhnke M, Penack O, Salwender H, Wolf HH, Christopeit M, Neumann S, Maschmeyer G, Karthaus M, Infectious Diseases Working Party of the German Society of H, Medical O (2014) Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. Ann Oncol 25(5):936–947. https://doi.org/10.1093/annonc/mdt545
doi: 10.1093/annonc/mdt545
pubmed: 24399078
Schmidt-Hieber M, Silling G, Schalk E, Heinz W, Panse J, Penack O, Christopeit M, Buchheidt D, Meyding-Lamade U, Hahnel S, Wolf HH, Ruhnke M, Schwartz S, Maschmeyer G (2016) CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation) - Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 27(7):1207–1225. https://doi.org/10.1093/annonc/mdw155
doi: 10.1093/annonc/mdw155
pubmed: 27052648
pmcid: 4922317
Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely OA, Donnelly JP, Garbino J, Groll AH, Hope WW, Jensen HE, Kullberg BJ, Lass-Florl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Cuenca-Estrella M, Group EFIS (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18(Suppl 7):53–67. https://doi.org/10.1111/1469-0691.12041
doi: 10.1111/1469-0691.12041
pubmed: 23137137
Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-Leon DE, Drgona L, Groll AH, Guinea J, Heussel CP, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee DG, Lehrnbecher T, Lmimouni BE, Mares M, Maschmeyer G, Meis JF, Meletiadis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M, Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, Vehreschild M, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A, Mucormycosis EMSGGGWG (2019) Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 19(12):e405–e421. https://doi.org/10.1016/S1473-3099(19)30312-3
doi: 10.1016/S1473-3099(19)30312-3
pubmed: 31699664
Bodey GP (1966) Infectious complications of acute leukemia. Medical Times 94(9):1076–1085
pubmed: 5946471
Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D, Hulin C, Fruchart C, Marit G, Pegourie B, Lenain P, Araujo C, Kolb B, Randriamalala E, Royer B, Stoppa AM, Dib M, Dorvaux V, Garderet L, Mathiot C, Avet-Loiseau H, Harousseau JL, Attal M, Intergroupe Francophone d M (2010) Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 115(1):32–37. https://doi.org/10.1182/blood-2009-06-229658
doi: 10.1182/blood-2009-06-229658
pubmed: 19884643
Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, Bence-Bruckler I, Birch P, Bredeson C, Chen J, Fergusson D, Halpenny M, Hamelin L, Huebsch L, Hutton B, Laneuville P, Lapierre Y, Lee H, Martin L, McDiarmid S, O'Connor P, Ramsay T, Sabloff M, Walker L, Freedman MS (2016) Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet 388(10044):576–585. https://doi.org/10.1016/S0140-6736(16)30169-6
doi: 10.1016/S0140-6736(16)30169-6
pubmed: 27291994
Muraro PA, Robins H, Malhotra S, Howell M, Phippard D, Desmarais C, de Paula Alves Sousa A, Griffith LM, Lim N, Nash RA, Turka LA (2014) T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest 124 (3):1168–1172. doi: https://doi.org/10.1172/JCI71691
Darlington PJ, Stopnicki B, Touil T, Doucet JS, Fawaz L, Roberts ME, Boivin MN, Arbour N, Freedman MS, Atkins HL, Bar-Or A (2018) Natural killer cells regulate Th17 cells after autologous hematopoietic stem cell transplantation for relapsing remitting multiple sclerosis. Front Immunol 9:834. https://doi.org/10.3389/fimmu.2018.00834
doi: 10.3389/fimmu.2018.00834
pubmed: 29867923
pmcid: 5951114
Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E, Donelli A, Lugaresi A, Di Bartolomeo P, Rottoli MR, Rambaldi A, Amato MP, Massacesi L, Di Gioia M, Vuolo L, Curro D, Roccatagliata L, Filippi M, Aguglia U, Iacopino P, Farge D, Saccardi R, Astims Haemato-Neurological Collaborative Group ObotADWPotEGfB, Marrow T, Blood AH-NCGObotADWPAotEGf, Marrow Transplantation E (2015) Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 84(10):981–988. https://doi.org/10.1212/WNL.0000000000001329
doi: 10.1212/WNL.0000000000001329
pubmed: 25672923
van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kotter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quere I, Rich E, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socie G, Gratwohl A, Tyndall A, Group EESS (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA: J Am Med Assoc 311(24):2490–2498. https://doi.org/10.1001/jama.2014.6368
doi: 10.1001/jama.2014.6368
Veeraputhiran M, Jain T, Deol A, Ayash L, Kim S, Dyson G, Bhutani D, Lum LG, Ratanatharathorn V, Uberti JP, Abidi MH (2015) BEAM conditioning regimen has higher toxicity compared with high-dose melphalan for salvage autologous hematopoietic stem cell transplantation in multiple myeloma. Clin Lymphoma Myeloma Leuk 15(9):531–535. https://doi.org/10.1016/j.clml.2015.05.008
doi: 10.1016/j.clml.2015.05.008
pubmed: 26166312
Ghazal SS, Stevens MP, Bearman GM, Edmond MB (2014) Utility of surveillance blood cultures in patients undergoing hematopoietic stem cell transplantation. Antimicrob Resist Infect Control 3:20. https://doi.org/10.1186/2047-2994-3-20
doi: 10.1186/2047-2994-3-20
pubmed: 24999384
pmcid: 4082284
Nesher L, Chemaly RF, Shah DP, Mulanovich VE, Hosing C, Rolston KV (2014) Utility of routine surveillance blood cultures in asymptomatic allogeneic hematopoietic stem cell transplant recipients with indwelling central venous catheters at a comprehensive cancer center. Am J Infect Control 42(10):1084–1088. https://doi.org/10.1016/j.ajic.2014.07.004
doi: 10.1016/j.ajic.2014.07.004
pubmed: 25278398
Metan G, Koc AN, Kaynar LG, Atalay A, Ozturk A, Eser B, Cetin M (2013) What is the role of the (1-->3)-beta-D-glucan assay in the screening of patients undergoing autologous haematopoietic stem-cell transplantation? Mycoses 56(1):34–38. https://doi.org/10.1111/j.1439-0507.2012.02195.x
doi: 10.1111/j.1439-0507.2012.02195.x
pubmed: 22497588
Pischke S, Hiller J, Lutgehetmann M, Polywka S, Rybczynski M, Ayuk F, Lohse AW (2016) Blood-borne hepatitis E virus transmission: a relevant risk for immunosuppressed patients. Clin Infect Dis 63(4):569–570. https://doi.org/10.1093/cid/ciw309
doi: 10.1093/cid/ciw309
pubmed: 27178472
Richtlinie zur Herstellung und Anwendung von hämatopoetischen Stammzellzubereitungen – Erste Fortschreibung (2019). Dtsch Arztebl. https://doi.org/10.3238/arztebl.2019.rl_haematop_sz02
Chen CY, Huang SY, Cheng A, Chou WC, Yao M, Tang JL, Tsay W, Sheng WH, Tien HF (2015) High risk of hepatitis B reactivation among patients with acute myeloid leukemia. PLoS One 10(5):e0126037. https://doi.org/10.1371/journal.pone.0126037
doi: 10.1371/journal.pone.0126037
pubmed: 25973905
pmcid: 4431821
Jun CH, Kim BS, Oak CY, Lee DH, Cho E, Cho SB, Choi SK, Park CH, Joo YE, Lee JJ, Kim HJ (2017) HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea. Hepatol Int 11(1):87–95. https://doi.org/10.1007/s12072-016-9747-0
doi: 10.1007/s12072-016-9747-0
pubmed: 27351765
Kim HY, Yoo JJ, Oh S, Yu SJ, Kim YJ, Yoon JH, Kim W, Jung YJ, Kim BH, Kim CM, Park JW, Lee JH (2018) Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: a multicenter study. J Med Virol 90(10):1593–1603. https://doi.org/10.1002/jmv.25241
doi: 10.1002/jmv.25241
pubmed: 29900560
Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, Fukushima N, Fukushima T, Moriuchi Y, Itoh K, Nosaka K, Choi I, Sawa M, Okamoto R, Tsujimura H, Uchida T, Suzuki S, Okamoto M, Takahashi T, Sugiura I, Onishi Y, Kohri M, Yoshida S, Sakai R, Kojima M, Takahashi H, Tomita A, Maruyama D, Atsuta Y, Tanaka E, Suzuki T, Kinoshita T, Ogura M, Mizokami M, Ueda R (2015) Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis 61(5):719–729. https://doi.org/10.1093/cid/civ344
doi: 10.1093/cid/civ344
pubmed: 25935551
Lv JW, Chen YP, Huang XD, Zhou GQ, Chen L, Li WF, Tang LL, Mao YP, Guo Y, Xu RH, Ma J, Sun Y (2017) Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: a large-scale, big-data intelligence platform-based analysis from an endemic area. Cancer 123(18):3540–3549. https://doi.org/10.1002/cncr.30775
doi: 10.1002/cncr.30775
pubmed: 28493307
von Lilienfeld-Toal M, Berger A, Christopeit M, Hentrich M, Heussel CP, Kalkreuth J, Klein M, Kochanek M, Penack O, Hauf E, Rieger C, Silling G, Vehreschild M, Weber T, Wolf HH, Lehners N, Schalk E, Mayer K (2016) Community acquired respiratory virus infections in cancer patients-guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology. Eur J Cancer 67:200–212. https://doi.org/10.1016/j.ejca.2016.08.015
doi: 10.1016/j.ejca.2016.08.015
von Lilienfeld-Toal M, Vehreschild JJ, Cornely O, Pagano L, Compagno F, Group EHAIDSW, Hirsch HH (2020) Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases. Leukemia 34 (6):1487–Group EHA1494. doi: https://doi.org/10.1038/s41375-020-0832-y
Lee A, Mirrett S, Reller LB, Weinstein MP (2007) Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol 45(11):3546–3548. https://doi.org/10.1128/JCM.01555-07
doi: 10.1128/JCM.01555-07
pubmed: 17881544
pmcid: 2168497
Cockerill FR 3rd, Wilson JW, Vetter EA, Goodman KM, Torgerson CA, Harmsen WS, Schleck CD, Ilstrup DM, Washington JA 2nd, Wilson WR (2004) Optimal testing parameters for blood cultures. Clin Infect Dis 38(12):1724–1730. https://doi.org/10.1086/421087
doi: 10.1086/421087
pubmed: 15227618
Guembe M, Rodriguez-Creixems M, Sanchez-Carrillo C, Perez-Parra A, Martin-Rabadan P, Bouza E (2010) How many lumens should be cultured in the conservative diagnosis of catheter-related bloodstream infections? Clin Infect Dis 50(12):1575–1579. https://doi.org/10.1086/652766
doi: 10.1086/652766
pubmed: 20455693
Seifert H, Cornely O, Seggewiss K, Decker M, Stefanik D, Wisplinghoff H, Fatkenheuer G (2003) Bloodstream infection in neutropenic cancer patients related to short-term nontunnelled catheters determined by quantitative blood cultures, differential time to positivity, and molecular epidemiological typing with pulsed-field gel electrophoresis. J Clin Microbiol 41(1):118–123. https://doi.org/10.1128/jcm.41.1.118-123.2003
doi: 10.1128/jcm.41.1.118-123.2003
pubmed: 12517836
pmcid: 149641
Blot F, Nitenberg G, Chachaty E, Raynard B, Germann N, Antoun S, Laplanche A, Brun-Buisson C, Tancrede C (1999) Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet 354(9184):1071–1077. https://doi.org/10.1016/s0140-6736(98)11134-0
doi: 10.1016/s0140-6736(98)11134-0
pubmed: 10509498
Park KH, Lee MS, Lee SO, Choi SH, Sung H, Kim MN, Kim YS, Woo JH, Kim SH (2014) Diagnostic usefulness of differential time to positivity for catheter-related candidemia. J Clin Microbiol 52(7):2566–2572. https://doi.org/10.1128/JCM.00605-14
doi: 10.1128/JCM.00605-14
pubmed: 24829236
pmcid: 4097682
Kaasch AJ, Rieg S, Hellmich M, Kern WV, Seifert H (2014) Differential time to positivity is not predictive for central line-related Staphylococcus aureus bloodstream infection in routine clinical care. J Inf Secur 68(1):58–61. https://doi.org/10.1016/j.jinf.2013.08.006
doi: 10.1016/j.jinf.2013.08.006
Bouzidi H, Emirian A, Marty A, Chachaty E, Laplanche A, Gachot B, Blot F (2018) Differential time to positivity of central and peripheral blood cultures is inaccurate for the diagnosis of Staphylococcus aureus long-term catheter-related sepsis. J Hosp Infect 99(2):192–199. https://doi.org/10.1016/j.jhin.2018.01.010
doi: 10.1016/j.jhin.2018.01.010
pubmed: 29432818
Patsios D, Maimon N, Chung T, Roberts H, Disperati P, Minden M, Paul N (2010) Chest low-dose computed tomography in neutropenic acute myeloid leukaemia patients. Respir Med 104(4):600–605. https://doi.org/10.1016/j.rmed.2009.11.003
doi: 10.1016/j.rmed.2009.11.003
pubmed: 20015630
Gerritsen MG, Willemink MJ, Pompe E, van der Bruggen T, van Rhenen A, Lammers JW, Wessels F, Sprengers RW, de Jong PA, Minnema MC (2017) Improving early diagnosis of pulmonary infections in patients with febrile neutropenia using low-dose chest computed tomography. PLoS One 12(2):e0172256. https://doi.org/10.1371/journal.pone.0172256
doi: 10.1371/journal.pone.0172256
pubmed: 28235014
pmcid: 5325310
Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del Favero A, Gruppo Italiano Malattie Ematologiche dell'Adulto Infection P (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353(10):977–987. https://doi.org/10.1056/NEJMoa044097
doi: 10.1056/NEJMoa044097
pubmed: 16148283
Fluoroquinolone and quinolone antibiotics: PRAC recommends restrictions on use. (2018). European Medicines Agency EMA/668915/2018
Bow EJ (2011) Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 24(6):545–553. https://doi.org/10.1097/QCO.0b013e32834cf054
doi: 10.1097/QCO.0b013e32834cf054
pubmed: 22001945
Mullane KM, Winston DJ, Nooka A, Morris MI, Stiff P, Dugan MJ, Holland H, Gregg K, Adachi JA, Pergam SA, Alexander BD, Dubberke ER, Broyde N, Gorbach SL, Sears PS (2019) A randomized, placebo-controlled trial of fidaxomicin for prophylaxis of Clostridium difficile-associated diarrhea in adults undergoing hematopoietic stem cell transplantation. Clin Infect Dis 68(2):196–203. https://doi.org/10.1093/cid/ciy484
doi: 10.1093/cid/ciy484
pubmed: 29893798
Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N (1999) Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 28(2):331–340. https://doi.org/10.1086/515128
doi: 10.1086/515128
pubmed: 10064252
van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ, National Institute of A, Infectious Diseases Mycoses Study G (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39(10):1407–1416. https://doi.org/10.1086/422312
doi: 10.1086/422312
pubmed: 15546073
Hicheri Y, Einsele H, Martino R, Cesaro S, Ljungman P, Cordonnier C (2013) Environmental prevention of infection in stem cell transplant recipients: a survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Transpl Infect Dis 15(3):251–258. https://doi.org/10.1111/tid.12064
doi: 10.1111/tid.12064
pubmed: 23465046
Vokurka S, Bystricka E, Svoboda T, Skoda Gorican IK, Sever M, Mazur E, Kopinska A, Pavlicova V, Mocanu O, Tanase A, Ghelase R, Zitkova M, Labudikova M, Raida L, Hrabankova-Navratilova D, Bockova J (2014) The availability of HEPA-filtered rooms and the incidence of pneumonia in patients after haematopoietic stem cell transplantation (HSCT): results from a prospective, multicentre, eastern European study. J Clin Nurs 23(11–12):1648–1652. https://doi.org/10.1111/jocn.12286
doi: 10.1111/jocn.12286
pubmed: 24354726
Stern A, Green H, Paul M, Vidal L, Leibovici L (2014) Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 10:CD005590. https://doi.org/10.1002/14651858.CD005590.pub3
doi: 10.1002/14651858.CD005590.pub3
Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, Lopez-Jimenez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Perez de Oteyza J, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM, Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer EA, Sullivan KM, Collaborators Z-HSG (2019) Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA: J Am Med Assoc 322(2):123–133. https://doi.org/10.1001/jama.2019.9053
doi: 10.1001/jama.2019.9053
Curran D, Matthews S, Rowley SD, Young JH, Bastidas A, Anagnostopoulos A, Barista I, Chandrasekar PH, Dickinson M, El Idrissi M, Heras I, Milliken ST, Monserrat Coll J, Navarro Matilla MB, Oostvogels L, Piatkowska-Jakubas B, Quiel D, Sabry W, Schwartz S, Selleslag DLD, Sullivan KM, Theunissen K, Yegin ZA, Yeh SP, Zaja F, Szer J, Z-HSg c (2019) Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT). Biol Blood Marrow Transplant 25(12):2474–2481. https://doi.org/10.1016/j.bbmt.2019.07.036
doi: 10.1016/j.bbmt.2019.07.036
pubmed: 31394276
Winston DJ, Mullane KM, Cornely OA, Boeckh MJ, Brown JW, Pergam SA, Trociukas I, Zak P, Craig MD, Papanicolaou GA, Velez JD, Panse J, Hurtado K, Fernsler DA, Stek JE, Pang L, Su SC, Zhao Y, Chan ISF, Kaplan SS, Parrino J, Lee I, Popmihajlov Z, Annunziato PW, Arvin A, Team VPT (2018) Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet 391(10135):2116–2127. https://doi.org/10.1016/S0140-6736(18)30631-7
doi: 10.1016/S0140-6736(18)30631-7
pubmed: 29856344
Kawamura K, Hayakawa J, Akahoshi Y, Harada N, Nakano H, Kameda K, Ugai T, Wada H, Yamasaki R, Ishihara Y, Sakamoto K, Ashizawa M, Sato M, Terasako-Saito K, Kimura S, Kikuchi M, Nakasone H, Yamazaki R, Kanda J, Kako S, Tanihara A, Nishida J, Kanda Y (2015) Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation. Int J Hematol 102(2):230–237. https://doi.org/10.1007/s12185-015-1810-4
doi: 10.1007/s12185-015-1810-4
pubmed: 25990803
McDonald EM, de Kock J, Ram FS (2012) Antivirals for management of herpes zoster including ophthalmicus: a systematic review of high-quality randomized controlled trials. Antivir Ther 17(2):255–264. https://doi.org/10.3851/IMP2011
doi: 10.3851/IMP2011
pubmed: 22300753
Lin PC, Lee MY, Lin JT, Hsiao LT, Chen PM, Chiou TJ (2008) Virus reactivation in high-risk non-Hodgkin's lymphoma patients after autologous CD34+-selected peripheral blood progenitor cell transplantation. Int J Hematol 87(4):434–439. https://doi.org/10.1007/s12185-008-0053-z
doi: 10.1007/s12185-008-0053-z
pubmed: 18317882
Jain T, John J, Kotecha A, Deol A, Saliminia T, Revankar S, Chandrasekar P (2016) Cytomegalovirus infection in autologous stem cell transplant recipients in the era of rituximab. Ann Hematol 95(8):1323–1327. https://doi.org/10.1007/s00277-016-2700-4
doi: 10.1007/s00277-016-2700-4
pubmed: 27225264
Mengarelli A, Annibali O, Pimpinelli F, Riva E, Gumenyuk S, Renzi D, Cerchiara E, Piccioni L, Palombi F, Pisani F, Romano A, Spadea A, Papa E, Cordone I, Canfora M, Arcese W, Ensoli F, Marchesi F (2016) Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant. J Infect 72(2):265–268. https://doi.org/10.1016/j.jinf.2015.11.005
doi: 10.1016/j.jinf.2015.11.005
pubmed: 26687516
Balsat M, Pillet S, Tavernier E, Cacheux V, Escuret V, Molucon-Chabrot C, Augeul-Meunier K, Mirand A, Regagnon C, Tinquaut F, Bousser V, Oriol M, Guyotat D, Salles G, Bay JO, Pozzetto B, Cornillon J (2019) Human herpesvirus 6 infection after autologous stem cell transplantation: a multicenter prospective study in adult patients. J Infect 79(1):36–42. https://doi.org/10.1016/j.jinf.2019.05.001
doi: 10.1016/j.jinf.2019.05.001
pubmed: 31075291
Inazawa N, Hori T, Nojima M, Saito M, Igarashi K, Yamamoto M, Shimizu N, Yoto Y, Tsutsumi H (2017) Virus reactivations after autologous hematopoietic stem cell transplantation detected by multiplex PCR assay. J Med Virol 89(2):358–362. https://doi.org/10.1002/jmv.24621
doi: 10.1002/jmv.24621
pubmed: 27364410
Mehra V, Rhone E, Widya S, Zuckerman M, Potter V, Raj K, Kulasekararaj A, McLornan D, de Lavallade H, Benson-Quarm N, Lim C, Ware S, Sudhanva M, Malik O, Nicholas R, Muraro PA, Marsh J, Mufti GJ, Silber E, Pagliuca A, Kazmi MA (2019) Epstein-Barr virus and monoclonal gammopathy of clinical significance in autologous stem cell transplantation for multiple sclerosis. Clin Infect Dis 69 (10):1757–1763. doi: https://doi.org/10.1093/cid/ciz047
EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection (2017) J Hepatol 67(2):370–398. https://doi.org/10.1016/j.jhep.2017.03.021
doi: 10.1016/j.jhep.2017.03.021
Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ (2009) Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49(5):1503–1514. https://doi.org/10.1002/hep.22841
doi: 10.1002/hep.22841
pubmed: 19280622
Jenh AM, Thio CL, Pham PA (2009) Tenofovir for the treatment of hepatitis B virus. Pharmacotherapy 29(10):1212–1227. https://doi.org/10.1592/phco.29.10.1212
doi: 10.1592/phco.29.10.1212
pubmed: 19792994
Choi J, Lim YS (2017) Characteristics, prevention, and management of hepatitis B virus (HBV) reactivation in HBV-infected patients who require immunosuppressive therapy. J Infect Dis 216(suppl_8):S778–S784. https://doi.org/10.1093/infdis/jix178
doi: 10.1093/infdis/jix178
pubmed: 29156044
Rieger CT, Liss B, Mellinghoff S, Buchheidt D, Cornely OA, Egerer G, Heinz WJ, Hentrich M, Maschmeyer G, Mayer K, Sandherr M, Silling G, Ullmann A, Vehreschild M, von Lilienfeld-Toal M, Wolf HH, Lehners N, German Society of H, Medical Oncology Infectious Diseases Working G (2018) Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Oncol 29(6):1354–1365. https://doi.org/10.1093/annonc/mdy117
doi: 10.1093/annonc/mdy117
pubmed: 29688266
pmcid: 6005139
Laws HJ, Baumann U, Bogdan C, Burchard G, Christopeit M, Hecht J, Heininger U, Hilgendorf I, Kern W, Kling K, Kobbe G, Kulper W, Lehrnbecher T, Meisel R, Simon A, Ullmann A, de Wit M, Zepp F (2020). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 63 (5):588–644. doi: https://doi.org/10.1007/s00103-020-03123-w
Bucaneve G, Micozzi A, Picardi M, Ballanti S, Cascavilla N, Salutari P, Specchia G, Fanci R, Luppi M, Cudillo L, Cantaffa R, Milone G, Bocchia M, Martinelli G, Offidani M, Chierichini A, Fabbiano F, Quarta G, Primon V, Martino B, Manna A, Zuffa E, Ferrari A, Gentile G, Foa R, Del Favero A (2014) Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. J Clin Oncol 32(14):1463–1471. https://doi.org/10.1200/JCO.2013.51.6963
doi: 10.1200/JCO.2013.51.6963
pubmed: 24733807
Toya T, Nannya Y, Narukawa K, Ichikawa M, Kurokawa M (2012) A comparative analysis of meropenem and doripenem in febrile patients with hematologic malignancies: a single-center retrospective study. Jpn J Infect Dis 65(3):228–232. https://doi.org/10.7883/yoken.65.228
doi: 10.7883/yoken.65.228
pubmed: 22627304
Hachem R, Reitzel R, Rolston K, Chaftari AM, Raad I (2017) Antimicrobial activities of ceftazidime-avibactam and comparator agents against clinical bacteria isolated from patients with cancer. Antimicrob Agents Chemother 61(4):e02106–e02116. https://doi.org/10.1128/AAC.02106-16
doi: 10.1128/AAC.02106-16
pubmed: 28115350
pmcid: 5365661
Aitken SL, Kontoyiannis DP, DePombo AM, Bhatti MM, Tverdek FP, Gettys SC, Nicolau DP, Nunez CA (2016) Use of ceftolozane/tazobactam in the treatment of multidrug-resistant Pseudomonas aeruginosa bloodstream infection in a pediatric leukemia patient. Pediatr Infect Dis J 35(9):1040–1042. https://doi.org/10.1097/INF.0000000000001228
doi: 10.1097/INF.0000000000001228
pubmed: 27254038
Nakane T, Tamura K, Hino M, Tamaki T, Yoshida I, Fukushima T, Tatsumi Y, Nakagawa Y, Hatanaka K, Takahashi T, Akiyama N, Tanimoto M, Ohyashiki K, Urabe A, Masaoka T, Kanamaru A, Japan Febrile Neutropenia Study G (2015) Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: a multicenter prospective randomized trial. J Infect Chemother 21(1):16–22. https://doi.org/10.1016/j.jiac.2014.08.026
doi: 10.1016/j.jiac.2014.08.026
pubmed: 25239059
Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA, Falagas ME (2005) Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials. Lancet Infect Dis 5(7):431–439. https://doi.org/10.1016/S1473-3099(05)70164-X
doi: 10.1016/S1473-3099(05)70164-X
pubmed: 15978529
Lisboa LF, Miranda BG, Vieira MB, Dulley FL, Fonseca GG, Guimaraes T, Levin AS, Shikanai-Yasuda MA, Costa SF (2015) Empiric use of linezolid in febrile hematology and hematopoietic stem cell transplantation patients colonized with vancomycin-resistant Enterococcus spp. Int J Infect Dis 33:171–176. https://doi.org/10.1016/j.ijid.2015.02.001
doi: 10.1016/j.ijid.2015.02.001
pubmed: 25660090
Kamboj M, Cohen N, Huang YT, Kerpelev M, Jakubowski A, Sepkowitz KA, Papanicolaou GA, Seo SK (2019) Impact of empiric treatment for vancomycin-resistant Enterococcus in colonized patients early after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 25(3):594–598. https://doi.org/10.1016/j.bbmt.2018.11.008
doi: 10.1016/j.bbmt.2018.11.008
pubmed: 30448456
Del Favero A, Menichetti F, Martino P, Bucaneve G, Micozzi A, Gentile G, Furno P, Russo D, D'Antonio D, Ricci P, Martino B, Mandelli F, Gruppo Italiano Malattie Ematologiche dell'Adulto Infection P (2001) A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 33 (8):1295–1301. doi: https://doi.org/10.1086/322646
Furno P, Bucaneve G, Del Favero A (2002) Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2(4):231–242. https://doi.org/10.1016/s1473-3099(02)00241-4
doi: 10.1016/s1473-3099(02)00241-4
pubmed: 11937423
Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L (2013) Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev 2013(6):CD003038. https://doi.org/10.1002/14651858.CD003038.pub2
doi: 10.1002/14651858.CD003038.pub2
pmcid: 6457814
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad RKV II, Young JA, Wingard JR, Infectious Diseases Society of A (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52(4):e56–e93. https://doi.org/10.1093/cid/cir073
doi: 10.1093/cid/cir073
pubmed: 21258094
Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Glauser MP, Calandra T, Viscoli C, International Antimicrobial Therapy Group of the European Organization for Research Treatment of C (2003) Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 37(3):382–389. https://doi.org/10.1086/376637
doi: 10.1086/376637
pubmed: 12884163
Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, Dhedin N, Isnard F, Ades L, Kuhnowski F, Foulet F, Kuentz M, Maison P, Bretagne S, Schwarzinger M (2009) Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 48(8):1042–1051. https://doi.org/10.1086/597395
doi: 10.1086/597395
pubmed: 19281327
Fung M, Kim J, Marty FM, Schwarzinger M, Koo S (2015) Meta-analysis and cost comparison of empirical versus pre-emptive antifungal strategies in hematologic malignancy patients with high-risk febrile neutropenia. PLoS One 10(11):e0140930. https://doi.org/10.1371/journal.pone.0140930
doi: 10.1371/journal.pone.0140930
pubmed: 26554923
pmcid: 4640557
Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41 (9):1242–1250. doi: https://doi.org/10.1086/496927
von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani MT, Schnitzler P, Bettinger D, Thimme R, Xhaard A, Binder M, Ayuk F, Lohse AW, Cornelissen JJ, de Man RA, Mallet V (2019) The burden of hepatitis E among patients with haematological malignancies: a retrospective European cohort study. J Hepatol 71(3):465–472. https://doi.org/10.1016/j.jhep.2019.04.022
doi: 10.1016/j.jhep.2019.04.022
Furfaro E, Nicolini L, Della Vecchia A, Di Grazia C, Raiola AM, Varaldo R, Ferrando F, Barisione G, Bruzzone B, Angelucci E, Viscoli C, Mikulska M (2020) Hepatitis E virus infection in an Italian cohort of hematopoietic stem cell transplantation recipients: seroprevalence and infection. Biol Blood Marrow Transplant 26 (7):1355–1362. doi: https://doi.org/10.1016/j.bbmt.2020.03.012
Marchesi F, Pimpinelli F, Ensoli F, Mengarelli A (2018) Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant. Hematol Oncol 36(2):381–391. https://doi.org/10.1002/hon.2453
doi: 10.1002/hon.2453
pubmed: 28660653
Kaya AH, Tekgunduz E, Akpinar S, Batgi H, Bekdemir F, Kayikci O, Namdaroglu S, Ulu BU, Dal MS, Cakar MK, Korkmaz S, Altuntas F (2017) Is cytomegalovirus surveillance necessary for patients with low reactivation risk in an autologous hematopoietic cell transplantation setting? Transplant Proc 49(8):1911–1915. https://doi.org/10.1016/j.transproceed.2017.05.007
doi: 10.1016/j.transproceed.2017.05.007
pubmed: 28923647
Massoud R, Assi R, Fares E, Haffar B, Charafeddine M, Kreidieh N, Mahfouz R, Kanj SS, El Zakhem A, Kharfan-Dabaja M, Bazarbachi A, El Cheikh J (2017) Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation. J Clin Virol 95:36–41. https://doi.org/10.1016/j.jcv.2017.08.006
doi: 10.1016/j.jcv.2017.08.006
pubmed: 28843110
Piukovics K, Terhes G, Gurbity-Palfi T, Bereczki A, Rarosi F, Deak J, Borbenyi Z, Urban E (2017) Cytomegalovirus infection in patients with haematological diseases and after autologous stem cell transplantation as consolidation: a single-centre study. Ann Hematol 96(1):125–131. https://doi.org/10.1007/s00277-016-2831-7
doi: 10.1007/s00277-016-2831-7
pubmed: 27730340
Chiusolo P, Metafuni E, Cattani P, Piccirillo N, Santangelo R, Manzara S, Bellesi S, De Michele T, Leone G, Sica S (2010) Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy. J Clin Immunol 30(6):894–902. https://doi.org/10.1007/s10875-010-9454-x
doi: 10.1007/s10875-010-9454-x
pubmed: 20737201
Piukovics K, Borbenyi Z, Rajda C, Csomor A, Deak J, Terhes G (2014) Monitoring human herpesvirus-6 in patients with autologous stem cell transplantation. Vivo 28(6):1113–1117
Duarte RF, Sanchez-Ortega I, Cuesta I, Arnan M, Patino B, Fernandez de Sevilla A, Gudiol C, Ayats J, Cuenca-Estrella M (2014) Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis 59(12):1696–1702. https://doi.org/10.1093/cid/ciu673
doi: 10.1093/cid/ciu673
pubmed: 25165088
Hammarstrom H, Kondori N, Friman V, Wenneras C (2015) How to interpret serum levels of beta-glucan for the diagnosis of invasive fungal infections in adult high-risk hematology patients: optimal cut-off levels and confounding factors. Eur J Clin Microbiol Infect Dis 34(5):917–925. https://doi.org/10.1007/s10096-014-2302-9
doi: 10.1007/s10096-014-2302-9
pubmed: 25573536
Cornely OA, Leguay T, Maertens J, Vehreschild M, Anagnostopoulos A, Castagnola C, Verga L, Rieger C, Kondakci M, Harter G, Duarte RF, Allione B, Cordonnier C, Heussel CP, Morrissey CO, Agrawal SG, Donnelly JP, Bresnik M, Hawkins MJ, Garner W, Gokbuget N, AmBiGuard Study G (2017) Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother 72(8):2359–2367. https://doi.org/10.1093/jac/dkx133
doi: 10.1093/jac/dkx133
pubmed: 28575414
pmcid: 5890735
Bouza E, Alvarado N, Alcala L, Perez MJ, Rincon C, Munoz P (2007) A randomized and prospective study of 3 procedures for the diagnosis of catheter-related bloodstream infection without catheter withdrawal. Clin Infect Dis 44(6):820–826. https://doi.org/10.1086/511865
doi: 10.1086/511865
pubmed: 17304454
Planes AM, Calleja R, Bernet A, Campins-Marti M, Almirante B, Pumarola T, Fernandez-Hidalgo N (2016) Evaluation of the usefulness of a quantitative blood culture in the diagnosis of catheter-related bloodstream infection: comparative analysis of two periods (2002 and 2012). Enferm Infecc Microbiol Clin 34(8):484–489. https://doi.org/10.1016/j.eimc.2015.11.007
doi: 10.1016/j.eimc.2015.11.007
pubmed: 26778796
Herrera-Guerra AS, Garza-Gonzalez E, Martinez-Resendez MF, Llaca-Diaz JM, Camacho-Ortiz A (2015) Individual versus pooled multiple-lumen blood cultures for the diagnosis of intravascular catheter-related infections. Am J Infect Control 43(7):715–718. https://doi.org/10.1016/j.ajic.2015.02.028
doi: 10.1016/j.ajic.2015.02.028
pubmed: 25868651
Marchesi F, Cattaneo C, Criscuolo M, Delia M, Dargenio M, Del Principe MI, Spadea A, Fracchiolla NS, Melillo L, Perruccio K, Alati C, Russo D, Garzia M, Brociner M, Cefalo M, Armiento D, Cesaro S, Decembrino N, Mengarelli A, Tumbarello M, Busca A, Pagano L, Sorveglianza Epidemiologica Infezioni nelle Emopatie G (2019) A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: a prospective multicenter study of the SEIFEM group American Journal of Hematology 94 (10):1104–1112. doi: https://doi.org/10.1002/ajh.25585
Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ et al (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326(13):845–851. https://doi.org/10.1056/NEJM199203263261301
doi: 10.1056/NEJM199203263261301
pubmed: 1542320
Cornely OA, Hoenigl M, Lass-Florl C, Chen SC, Kontoyiannis DP, Morrissey CO, Thompson GR 3rd, Mycoses Study Group E, Research C, the European Confederation of Medical M (2019) Defining breakthrough invasive fungal infection-position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses 62(9):716–729. https://doi.org/10.1111/myc.12960
doi: 10.1111/myc.12960
pubmed: 31254420
pmcid: 6692208
Sun Y, Meng F, Han M, Zhang X, Yu L, Huang H, Wu D, Ren H, Wang C, Shen Z, Ji Y, Huang X (2015) Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study. Biol Blood Marrow Transplant 21(6):1117–1126. https://doi.org/10.1016/j.bbmt.2015.03.018
doi: 10.1016/j.bbmt.2015.03.018
pubmed: 25840339
Dadd G, McMinn P, Monterosso L (2003) Protective isolation in hemopoietic stem cell transplants: a review of the literature and single institution experience. J Pediatr Oncol Nurs 20(6):293–300. https://doi.org/10.1177/1043454203254985
doi: 10.1177/1043454203254985
pubmed: 14738161
Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T (2009) Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev 1:CD006706. https://doi.org/10.1002/14651858.CD006706.pub2
doi: 10.1002/14651858.CD006706.pub2
Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Rodriguez Macias G, Chiou TJ, Quiel D, Aoun M, Navarro Matilla MB, de la Serna J, Milliken S, Murphy J, McNeil SA, Salaun B, Di Paolo E, Campora L, Lopez-Fauqued M, El Idrissi M, Schuind A, Heineman TC, Van den Steen P, Oostvogels L, Zoster-039 s g (2019) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis 19(9):988–1000. https://doi.org/10.1016/S1473-3099(19)30163-X
Sahoo F, Hill JA, Xie H, Leisenring W, Yi J, Goyal S, Kimball LE, Lee I, Seo S, Davis C, Pergam SA, Flowers ME, Liaw KL, Holmberg L, Boeckh M (2017) Herpes zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies. Biol Blood Marrow Transplant 23(3):505–511. https://doi.org/10.1016/j.bbmt.2016.12.620
doi: 10.1016/j.bbmt.2016.12.620
pubmed: 28039754
Seo HM, Kim YS, Bang CH, Lee JH, Lee JY, Lee DG, Park YM (2017) Antiviral prophylaxis for preventing herpes zoster in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Antivir Res 140:106–115. https://doi.org/10.1016/j.antiviral.2017.01.011
doi: 10.1016/j.antiviral.2017.01.011
pubmed: 28132866
Crippa F, Holmberg L, Carter RA, Hooper H, Marr KA, Bensinger W, Chauncey T, Corey L, Boeckh M (2002) Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 8(5):281–289. https://doi.org/10.1053/bbmt.2002.v8.pm12064366
doi: 10.1053/bbmt.2002.v8.pm12064366
pubmed: 12064366
Boeckh M, Gooley TA, Reusser P, Buckner CD, Bowden RA (1995) Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. J Infect Dis 172(4):939–943. https://doi.org/10.1093/infdis/172.4.939
doi: 10.1093/infdis/172.4.939
pubmed: 7561213
Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD (2013) Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 31(22):2765–2772. https://doi.org/10.1200/JCO.2012.48.5938
doi: 10.1200/JCO.2012.48.5938
pubmed: 23775967
Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, Zhang HY, Lie A, Ngan R, Liang R (2003) Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125(6):1742–1749. https://doi.org/10.1053/j.gastro.2003.09.026
doi: 10.1053/j.gastro.2003.09.026
pubmed: 14724827
Reich G, Cornely OA, Sandherr M, Kubin T, Krause S, Einsele H, Thiel E, Bellaire T, Dorken B, Maschmeyer G (2005) Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. Br J Haematol 130(2):265–270. https://doi.org/10.1111/j.1365-2141.2005.05608.x
doi: 10.1111/j.1365-2141.2005.05608.x
pubmed: 16029455
Horita N, Shibata Y, Watanabe H, Namkoong H, Kaneko T (2017) Comparison of antipseudomonal beta-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis. Clin Microbiol Infect 23(10):723–729. https://doi.org/10.1016/j.cmi.2017.03.024
doi: 10.1016/j.cmi.2017.03.024
pubmed: 28377312
Harter C, Schulze B, Goldschmidt H, Benner A, Geiss HK, Hoppe-Tichy T, Ho AD, Egerer G (2006) Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant 37(4):373–379. https://doi.org/10.1038/sj.bmt.1705256
doi: 10.1038/sj.bmt.1705256
pubmed: 16400334
Bow EJ, Rotstein C, Noskin GA, Laverdiere M, Schwarer AP, Segal BH, Seymour JF, Szer J, Sanche S (2006) A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 43(4):447–459. https://doi.org/10.1086/505393
doi: 10.1086/505393
pubmed: 16838234
Maschmeyer G, Heinz WJ, Hertenstein B, Horst HA, Requadt C, Wagner T, Cornely OA, Loffler J, Ruhnke M, Is i (2013) Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study. Eur J Clin Microbiol Infect Dis 32(5):679–689. https://doi.org/10.1007/s10096-012-1794-4
doi: 10.1007/s10096-012-1794-4
pubmed: 23271674
Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351(14):1391–1402. https://doi.org/10.1056/NEJMoa040446
doi: 10.1056/NEJMoa040446
pubmed: 15459300
Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340(10):764–771. https://doi.org/10.1056/NEJM199903113401004
doi: 10.1056/NEJM199903113401004
pubmed: 10072411